Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
about
Concerns about quetiapinePotential drug-drug interactions in Alzheimer patients with behavioral symptomsUse of atypical antipsychotics in the elderly: a clinical reviewImproving the predictive value of interventional animal models dataPharmacological management of behavioral symptoms associated with dementiaNurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised TrialDopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicityEvaluation of the antipsychotic medication review process at four long-term facilities in AlbertaDifferences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations.Effect of medications on physical function and cognition in nursing home residents with dementiaPsychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder.Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.Comparative safety of antipsychotic medications in nursing home residentsCNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based studyNMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Relapse risk after discontinuation of risperidone in Alzheimer's disease.Atypical antipsychotic use in patients with dementia: managing safety concerns.Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based studyCognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective studyMolecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Pharmacotherapeutic management of dementia across settings of care.ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.CSF prion protein concentration and cognition in patients with Alzheimer diseaseDifferential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.Quality improvement in neurology: dementia management quality measures.ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Quality improvement in neurology: dementia management quality measures (executive summary)A review: treatment of Alzheimer's disease discovered in repurposed agents.Quality improvement in neurology: dementia management quality measures.Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice.Late-life psychosis: diagnosis and treatment.Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.Herbal medicine for management of the behavioural and psychological symptoms of dementia (BPSD): A systematic review and meta-analysis.Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease.
P2860
Q26773288-F258AA3A-81D6-4BA5-9292-891A5A02B17CQ26782490-6BAB3633-29A6-424D-8E79-24725C5B3A4DQ26827756-E9A1B9FE-0104-4487-AA13-FD151EAE4626Q27026822-0F33DF3A-ECCC-42D1-8C38-052874493591Q28081955-86CDB017-F2C3-4822-A67D-4FFEC6C06EBAQ28550194-BA963217-A829-4A8E-BE52-75E49D5EB640Q30535414-B71AE411-40CD-4A89-A9BE-62BDEA7BDC0DQ30822116-B4DBE5AC-944D-40DA-80F6-5C4A07D3CAB7Q33617259-2492B141-95F4-4D29-AB5A-88F6B8DF82C1Q34103934-823785D2-42A6-4BD5-A299-C8DA46C63FC6Q34139476-AD8EB6BF-003E-49CE-A44C-3BC8E9575FCAQ34438066-F0B727CB-006C-4992-9E1E-E3B4B7EF7E9DQ34452896-B71BE364-B546-4ED8-AC08-510813189F2FQ35828059-586291E4-3CD4-446A-ADEF-CB12754CBCFEQ35953332-20A565AF-C3A8-45EB-8376-65150CE693FAQ36310524-D73AD0E3-9DAD-4D08-9F44-11BD0529D4C5Q36375421-F19F1298-B762-41D6-B177-0CECECD4ED13Q36450333-B512C446-73A2-48CF-8E1D-EB45B6515717Q36588166-4EC5577D-433B-48BC-BDE6-A9CFC7758181Q36670523-72056BE4-F097-45B2-8277-525F14BAD2BAQ36706010-97D92552-244A-43BA-AAF2-69DB305680F5Q36724965-40221EB4-7672-4E04-A98F-EF041245A6B7Q36849968-CD4E8628-28AA-4C75-B9A6-10121098BD16Q36901247-899D7B53-28DA-443E-B216-7E171DC76147Q37197675-972F4048-846A-4364-AD23-A5ABDAB5DB48Q37331835-77DE0C4F-CA95-4444-A6F0-DFB1CA662320Q37463452-D4C67BC7-78E2-492C-BBCF-55B4CF409486Q37585410-885EC5E9-CF4D-45DA-A1DD-D1549A3CA292Q37693772-239A0D4F-A0A6-414C-8363-90F3418632BBQ37713850-0CB0642B-591E-4342-B7DF-DCB0E8F4B03DQ38073138-82A23AC3-222D-46CE-A2F1-9D30AA19F406Q38176435-8DA45B13-C6E3-4A99-988E-F5DB213EB186Q38182842-3080ED50-99C3-4E44-9654-1B3550CBB239Q38330595-272DCC02-CC9F-4C38-8D1F-6DA6EA0EAAE6Q38350551-6E2C5272-4953-4224-A745-79D3E0CA7334Q38628803-C9351851-45B2-49BC-96BC-61E94FA44394Q38693438-F4C323D9-F79B-4C56-9551-1C41AA420AF5Q38700484-E373C5B9-CEAB-4582-9D16-8AE3A830506CQ39023920-73716F86-A7E3-4584-AF73-583FE4E03E8AQ39307470-DA8D417C-C146-479B-A41D-D69F4FF486FC
P2860
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@ast
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@en
type
label
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@ast
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@en
prefLabel
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@ast
Cognitive effects of atypical ...... sease: outcomes from CATIE-AD.
@en
P2093
P2860
P1476
Cognitive effects of atypical ...... isease: outcomes from CATIE-AD
@en
P2093
Cheryl L P Vigen
Constantine G Lyketsos
David L Sultzer
John K Hsiao
Karen S Dagerman
Ling Zheng
Lon S Schneider
Pierre N Tariot
Richard S E Keefe
P2860
P304
P356
10.1176/APPI.AJP.2011.08121844
P407
P577
2011-05-15T00:00:00Z